Mettu, N. B., Twohy, E., Ou, F.-S., Halfdanarson, T. R., Lenz, H. J., Breakstone, R., … Bekaii-Saab, T. (2019). BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study. In ANNALS OF ONCOLOGY (Vol. 30). Barcelona, SPAIN: OXFORD UNIV PRESS.

Mettu, N. B., E. Twohy, F. -. S. Ou, T. R. Halfdanarson, H. J. Lenz, R. Breakstone, P. M. Boland, et al. “BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study.” In ANNALS OF ONCOLOGY, Vol. 30. OXFORD UNIV PRESS, 2019.

Mettu NB, Twohy E, Ou F-S, Halfdanarson TR, Lenz HJ, Breakstone R, et al. BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study. In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2019.

Mettu, N. B., et al. “BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study.” ANNALS OF ONCOLOGY, vol. 30, OXFORD UNIV PRESS, 2019.

Mettu NB, Twohy E, Ou F-S, Halfdanarson TR, Lenz HJ, Breakstone R, Boland PM, Crysler O, Wu C, Grothey A, Nixon AB, Bolch E, Niedzwiecki D, Fruth B, Schweitzer B, Elsing A, Hurwitz H, Fakih MG, Bekaii-Saab T. BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study. ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2019.